Retatrutide Phase 3 Trial Shows Strong Weight Loss Results in Obesity and Type 2 Diabetes
A large Phase 3 trial has added weight to the case for retatrutide as a possible future treatment for adults living with both obesity and type 2 diabetes.
The study, published in The Lancet on 29 September 2026, reported substantial average weight loss over 80 weeks in people receiving weekly retatrutide injections. Blood glucose control also improved, which matters because weight and glucose management are closely linked in type 2 diabetes care.
The results are promising, but they also need careful interpretation. The trial compared retatrutide with placebo, not with semaglutide or tirzepatide. That means the findings do not prove retatrutide is better than those medicines.
What the TRIUMPH-2 trial studied
The TRIUMPH-2 trial enrolled 1,152 adults with obesity and type 2 diabetes. Participants received either retatrutide or placebo as a weekly injection for 80 weeks.
Retatrutide is designed to act on three hormone receptors involved in metabolism:
GIP
GLP-1
Glucagon
That triple-receptor approach is one reason the medicine has drawn attention. Current weight loss medicines such as semaglutide and tirzepatide also act through gut-hormone pathways, but they do not target the same three receptors in the same way.
In the trial, researchers tested three retatrutide doses:
4 mg
9 mg
12 mg
They compared those groups with a placebo group. A placebo is an inactive treatment used to help researchers measure how much effect comes from the study drug itself rather than trial participation, lifestyle advice, expectation, or other factors.
The main findings focused on body weight change. Researchers also assessed blood glucose control and adverse events.
The weight loss results were large across all retatrutide groups
Average weight loss was higher with retatrutide than with placebo at 80 weeks. The strongest average result appeared in the 12 mg group.
Treatment group | Average weight loss |
Retatrutide 4 mg | 11.9% |
Retatrutide 9 mg | 16.8% |
Retatrutide 12 mg | 18.8% |
Placebo | 5.1% |
For context, a percentage weight loss figure reflects a change from a person’s starting body weight. A 10% reduction is often seen as clinically meaningful in obesity care, although the health impact varies from person to person.
The placebo group also lost weight on average. That is not unusual in obesity trials. People enrolled in studies may receive structured monitoring, lifestyle guidance, regular follow-up, and stronger accountability than they would outside a trial. Those factors can lead to weight loss even without an active medicine.
Still, the difference between the placebo group and the retatrutide groups was clear in the reported averages. The 12 mg group had an average reduction more than three times that seen with placebo.
The trial found average weight loss of 18.8% with retatrutide 12 mg over 80 weeks, compared with 5.1% with placebo.
These figures support further interest in retatrutide for people who need treatment for obesity and type 2 diabetes together.
Blood glucose control also improved
The study also reported better blood glucose control in people treated with retatrutide.
That finding is important because type 2 diabetes care is not only about weight. It also involves managing blood glucose, reducing cardiometabolic risk, and improving long-term health outcomes where possible.
GLP-1 based medicines can help with glucose regulation by affecting insulin and glucagon responses, slowing stomach emptying, and reducing appetite. GIP and glucagon receptor activity add further complexity. Retatrutide’s design means researchers are studying whether a broader hormonal effect can produce greater weight loss while also supporting glucose control.
The trial results suggest that retatrutide may help on both fronts. The strongest public focus will likely sit on weight loss, because the numbers are large. But for people with type 2 diabetes, glucose outcomes are a major part of the clinical picture.
A medicine that reduces weight but worsens glucose would be far less useful in this group. In this trial, glucose control moved in the right direction.
That said, average trial results never predict one individual’s result with certainty. Some people lose more weight, some lose less, and some stop treatment because of side effects or other reasons.
Side effects were common and need close attention
The most common side effects were digestive symptoms, especially diarrhoea and nausea.
That pattern is familiar with medicines that act on gut-hormone pathways. Nausea, diarrhoea, constipation, vomiting, and reduced appetite are common issues in this treatment class. Symptoms may occur during dose increases and can affect whether someone is able to continue treatment.
In TRIUMPH-2, low blood pressure and altered skin sensations occurred more often with retatrutide than with placebo. These details matter because weight loss medicines are often discussed mainly in terms of kilograms or body weight percentage. Safety and tolerability are just as important.
The trial also reported that treatment discontinuation due to adverse events or death was higher in the 9 mg and 12 mg retatrutide groups than with placebo.
That does not mean the medicine caused every serious outcome. Clinical trials track events carefully, and people participating may have complex health risks at baseline. But the higher discontinuation rate in the higher-dose groups is a signal clinicians and regulators will need to examine closely.
The balance between benefit and risk may differ by dose. A higher dose may produce greater average weight loss, but it may also cause more side effects or treatment stoppages. In real clinical care, the best dose is rarely just the one with the largest average effect. It is the one that provides meaningful benefit with acceptable tolerability for the person taking it.
What makes retatrutide different from other weight loss medicines
Retatrutide is often described as a “triple agonist” because it targets GIP, GLP-1, and glucagon receptors.
Those terms can sound technical, but the broad idea is simple. These hormone pathways help regulate appetite, insulin response, energy balance, and metabolism. Medicines that act on these pathways can reduce hunger, change food intake, and improve glucose control.
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity as well.
That difference makes the medicine scientifically interesting, but it does not automatically make it better. Drug development depends on evidence from trials, including head-to-head comparisons, long-term safety data, real-world use, and regulatory review.
The TRIUMPH-2 findings show that retatrutide performed better than placebo in this trial population. They do not show whether it performs better, worse, or similarly compared with semaglutide or tirzepatide.
This distinction is essential. Placebo-controlled trials are useful for proving that a treatment works better than no active medicine under trial conditions. Head-to-head trials answer a different question: how a treatment compares with another active option.
Without that kind of comparison, claims of superiority would go beyond the evidence described in this study.
Why the placebo comparison matters
The trial design shapes what the results can and cannot tell us.
A placebo comparison helps researchers isolate the drug’s effect. It answers the question, “Did people receiving retatrutide lose more weight than people receiving an inactive injection?”
In this case, the answer was yes.
But the design does not answer questions such as:
Is retatrutide more effective than semaglutide?
Is retatrutide more effective than tirzepatide?
Does retatrutide have fewer or more side effects than those medicines?
Which medicine works best for people with different diabetes histories?
Which dose offers the best balance of benefit and tolerability?
Those questions need different studies.
The popularity of weight loss medicines has made comparisons tempting. People naturally want to know which option is “best”. Yet obesity and diabetes treatment is rarely that simple. Dose, tolerability, medical history, blood glucose targets, kidney function, cardiovascular risk, cost, access, and patient preference can all shape treatment decisions.
TRIUMPH-2 adds important evidence, but it is one part of a larger research picture.
The Eli Lilly funding should be read with transparency in mind
The trial was funded by Eli Lilly, the company developing retatrutide.
Industry funding does not automatically invalidate a study. Many large drug trials require resources that are usually supplied by pharmaceutical sponsors. Peer review, trial registration, ethics oversight, data monitoring, and regulatory review all play roles in assessing quality.
At the same time, funding sources should be clearly disclosed and considered when reading results. Independent analysis, further trials, and post-marketing safety monitoring, if a medicine is approved, all help build confidence in the evidence base.
For readers assessing the findings, the most balanced approach is to recognise both points:
The study provides strong placebo-controlled evidence of weight loss and glucose improvement.
The trial was large and ran for 80 weeks.
Higher doses produced greater average weight loss.
The sponsor had a commercial interest in the medicine being studied.
It did not compare retatrutide with semaglutide or tirzepatide.
Higher-dose groups also had more treatment discontinuation due to adverse events or death than placebo.
That is not a reason to dismiss the study. It is a reason to read it carefully.
What the results mean for adults with obesity and type 2 diabetes
The trial supports retatrutide’s potential as a future treatment option for obesity alongside type 2 diabetes. The average weight loss figures were substantial, and glucose control improved.
If further evidence supports these findings, retatrutide could become part of a growing group of medicines aimed at treating obesity as a chronic metabolic disease rather than a short-term lifestyle issue.
That shift matters. Obesity is linked with hormonal, genetic, environmental, behavioural, and social factors. Many people need more than advice to “eat less and move more”. Medicines can form one part of care when used with medical supervision, nutrition support, physical activity, and management of related conditions.
The results also reinforce how quickly this field is changing. A decade ago, average weight loss of this size from a medication would have seemed unlikely. Now, several gut-hormone based treatments are producing results that have changed clinical expectations.
Even so, the practical questions remain:
Who benefits most?
Who is more likely to experience side effects?
What happens after several years of treatment?
How should treatment be adjusted if weight plateaus?
What happens when treatment stops?
How will access and cost affect real-world use?
TRIUMPH-2 helps answer the question of whether retatrutide can produce meaningful weight loss in a studied population with obesity and type 2 diabetes. It does not settle all the questions that matter in routine care.
These research doses are not a personal treatment plan
The doses used in this trial should not be interpreted as advice for individual treatment.
Medication decisions for obesity and type 2 diabetes need a clinician who can assess the full picture. That includes current medicines, blood glucose patterns, blood pressure, kidney and liver health, gastrointestinal history, pregnancy plans, mental health, and previous responses to treatment.
It is also risky to view trial averages as a personal forecast. A reported average of 18.8% weight loss does not mean every person would lose that amount. Some people may lose more. Some may lose far less. Some may stop because of nausea, diarrhoea, low blood pressure, altered skin sensations, or other adverse events.
The safest reading is this: retatrutide showed strong results in a controlled Phase 3 trial, but individual treatment choices still need medical guidance.
This article is for general information only and is not medical advice. Anyone considering treatment for obesity, type 2 diabetes, or weight-related health concerns should speak with a qualified health professional.
The takeaway
The TRIUMPH-2 trial published in The Lancet reported strong average weight loss with weekly retatrutide in adults with obesity and type 2 diabetes. The 12 mg group lost an average of 18.8% of body weight over 80 weeks, compared with 5.1% in the placebo group. Blood glucose control also improved.
The safety findings deserve equal attention. Digestive symptoms were common, low blood pressure and altered skin sensations occurred more often with retatrutide, and discontinuation due to adverse events or death was higher in the 9 mg and 12 mg groups than with placebo.
The results make retatrutide one of the more closely watched medicines in obesity and diabetes research. They do not prove it is better than semaglutide or tirzepatide, because this trial did not test that question.
For now, the study offers a clear but measured message: retatrutide looks promising, but its place in care will depend on the full body of evidence, safety review, regulatory decisions, and how well people tolerate it outside trial conditions.
Comments